An­oth­er de­pres­sion tri­al goes bust, as Min­er­va drug fails PhII study

De­pres­sion tri­als tend to reap de­press­ing re­sults. On­ly weeks ago, Sage Ther­a­peu­tics’ keen­ly an­tic­i­pat­ed piv­otal tri­al in ma­jor de­pres­sive dis­or­der (MDD) missed the main goal — and now, Min­er­va Neu­ro­sciences’ own ef­fort in MDD has ground to a halt.

On Wednes­day, the Waltham, Mass­a­chu­setts-based drug de­vel­op­er said its 5-HT1A in­hibitor, MIN-117, failed to dom­i­nate the place­bo in a 360-pa­tient mid-stage tri­al in adults with mod­er­ate-to-se­vere MDD pre­sent­ing with anx­ious dis­tress.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER